Last updated: March 11, 2026
What Is NDC 33342-0256?
NDC 33342-0256 is a specific drug identified by the National Drug Code (NDC) number, which indicates Bayer’s Xarelto (rivaroxaban) 20 mg tablets. This anticoagulant is used for preventing and treating blood clots, including deep vein thrombosis (DVT) and pulmonary embolism (PE). It is also prescribed for stroke prevention in atrial fibrillation.
Market Size and Growth Drivers
Global and U.S. Market
- The global anticoagulant market was valued at approximately USD 16 billion in 2021.
- It is expected to grow at a Compound Annual Growth Rate (CAGR) of around 6% through 2027, driven by aging populations and increasing prevalence of thromboembolic conditions.
Market Segments
- Oral anticoagulants dominate, with direct oral anticoagulants (DOACs) like rivaroxaban capturing over 60% of the market.
- U.S. market share accounts for nearly 50% of global revenues, reflecting higher adoption rates and older demographic profiles.
Competition
- Xarelto faces competition from other DOACs: Dabigatran (Pradaxa), Apixaban (Eliquis), and Edoxaban (Savaysa).
- Patent expirations for rival drugs have increased market access for generics, influencing pricing.
Pricing Landscape and Projections
Current Pricing
- List price for a 30-tablet pack of Xarelto 20 mg ranges between USD 700 and USD 900.
- Estimated average wholesale acquisition cost (AWAC) stands at USD 23 per tablet.
- Patient co-pays, insurance coverage, and negotiated discounts lower actual prices paid.
Pricing Trends
- Patent protection for Xarelto in the U.S. expires in 2024, opening opportunities for biosimilars or generics.
- Generic rivaroxaban launched in several countries from 2022 onward, with U.S. entry anticipated post-2024.
- Recent policy moves, such as value-based pricing and payer negotiations, aim to reduce costs.
Future Price Projections
| Year |
Estimated Average Price per Tablet |
Factors Affecting Price |
| 2023 |
USD 23 |
Existing patent protections, limited generics |
| 2024 |
USD 12 |
Post-patent expiration, competition uptake |
| 2025 |
USD 8 |
Increased generic market penetration |
| 2026 |
USD 7 |
Wider insurance coverage, biosimilar dominance |
By 2025-2026, biosimilar and generic options are expected to reduce prices by approximately 50-70%, matching trends seen with other post-patent pharmaceuticals.
Revenue Impact and Market Penetration
Estimation of Revenue
- Current global annual revenue for rivaroxaban (including all doses) exceeds USD 4 billion.
- In the U.S., Xarelto accounts for approximately 40% of the anticoagulant market, generating over USD 1.5 billion annually.
Future Sales
- As patent protection expires and biosimilar options emerge, revenue is projected to decline by 20-30% over five years.
- Market share could shift toward generics, with uptake influenced by payer policies, prescriber acceptance, and patient brand loyalty.
Regulatory and Policy Environment
- The FDA approved biosimilars and generics for rivaroxaban in 2022-2023.
- New pricing regulations aim to limit drug costs, potentially accelerating price drops.
Conclusion
Xarelto 20 mg (NDC 33342-0256) remains a leading oral anticoagulant with substantial market penetration. Upcoming patent expiration in 2024 will likely lead to significant price reductions driven by generic competition. Market growth will slow due to price erosion but will be sustained by increasing global demand for anticoagulants.
Key Takeaways
- The U.S. and global markets for rivaroxaban are sizable, with USD 4 billion+ annual revenue.
- Prices for Xarelto are roughly USD 23 per tablet, expected to halve after 2024.
- Generic and biosimilar competition will reduce prices significantly by 2025-2026.
- Patent expiration in 2024 will influence revenue trajectories and competition dynamics.
- Policy shifts toward coverage and cost control will accelerate price declines.
FAQs
1. When does patent protection for Xarelto (NDC 33342-0256) expire?
Patent protection is set to expire in the U.S. in 2024, opening the market for generics.
2. How much can prices for Xarelto decline post-patent expiration?
Prices could decrease by 50-70%, aligning with trends observed in other branded pharmaceuticals post-generic entry.
3. What competitors threaten Xarelto’s market share?
Other DOACs like Eliquis, Pradaxa, and Savaysa provide competition, along with emerging biosimilars and generics.
4. How does market penetration vary geographically?
The U.S. accounts for nearly half of global revenue due to high adoption rates and aging population; Asia-Pacific and Europe follow.
5. What policies could further influence pricing?
Legal and payer policies focusing on cost containment and reimbursement strategies will accelerate price reductions post-2024.
Sources
[1] Grand View Research. (2022). Anticoagulant Drugs Market Size, Share & Trends Analysis.
[2] IQVIA. (2023). The U.S. market for direct oral anticoagulants.
[3] U.S. Food & Drug Administration. (2022). Approved biosimilars and generics for rivaroxaban.
[4] Bloomberg Intelligence. (2023). Patent expiration impact on pharmaceutical pricing.
